Risk of Bleeding Fibrinolytic drugs dissolve blood clots, including those formed naturally as a protective response to vessel injury, which can result in bleeding. The risk of intracranial hemorrhaging increases as the dosage increases. Patients who are already taking other medications to prevent formation of clots, such as anticoagulants or antiplatelets, may not be good candidates for the use of fibrinolytic drugs due to the increased difficulty of controlling bleeding. In the study that led to FDA approval of rt-PA, the incidence of SICH in rt-PA patients was 6.4%, compared to 0.6% in the placebo group. As a result, rt-PA is subject to strict limitations on when, how long and in what dosages it may be administered
EX-10.32 4 c75275exv10w32.htm EXHIBIT 10.32 Filed by Bowne Pure Compliance
EXHIBIT 10.32
Fiscal 2009 executive officer base salaries and fiscal 2008 bonus amounts
On September 11, 2008, the Board of Directors approved the following annual base salaries for the Companys executive officers, to be effective as of September 1, 2008. The Board of Directors also approved the following bonus amounts to be paid to the executive officers based on performance for fiscal 2008.
Name | Position | Base Salary | Bonus Amount | |||||||
Paul E. Freiman | President and Chief Executive Officer | $ | 420,000 | $ | 100,000 | |||||
Warren Wasiewski, M.D. | Vice President, Chief Medical Officer | $ | 320,000 | $ | 76,250 | |||||
Matthew M. Loar | Vice President, Chief Financial Officer | $ | 280,000 | $ | 17,188 | |||||
Karl G. Trass | Vice President, Regulatory Affairs & Quality Assurance | $ | 235,000 | $ | 44,100 | |||||
David E. Levy, M.D. | Vice President, Clinical Development | $ | 261,500 | $ | 25,625 |